DK3290441T3 - Rgma-bindingsprotein og anvendelse deraf - Google Patents

Rgma-bindingsprotein og anvendelse deraf Download PDF

Info

Publication number
DK3290441T3
DK3290441T3 DK16786512.0T DK16786512T DK3290441T3 DK 3290441 T3 DK3290441 T3 DK 3290441T3 DK 16786512 T DK16786512 T DK 16786512T DK 3290441 T3 DK3290441 T3 DK 3290441T3
Authority
DK
Denmark
Prior art keywords
binding protein
rgma binding
rgma
protein
binding
Prior art date
Application number
DK16786512.0T
Other languages
English (en)
Inventor
Motonori Hashimoto
Toshihide Yamashita
Original Assignee
Mitsubishi Tanabe Pharma Corp
Univ Osaka
Univ Chiba Nat Univ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp, Univ Osaka, Univ Chiba Nat Univ Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of DK3290441T3 publication Critical patent/DK3290441T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
DK16786512.0T 2015-04-28 2016-04-27 Rgma-bindingsprotein og anvendelse deraf DK3290441T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015091095 2015-04-28
PCT/JP2016/063166 WO2016175236A1 (ja) 2015-04-28 2016-04-27 ＲＧＭａ結合タンパク質及びその使用

Publications (1)

Publication Number Publication Date
DK3290441T3 true DK3290441T3 (da) 2020-01-02

Family

ID=57198582

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16786512.0T DK3290441T3 (da) 2015-04-28 2016-04-27 Rgma-bindingsprotein og anvendelse deraf

Country Status (33)

Country Link
US (3) US10287346B2 (da)
EP (2) EP3290441B1 (da)
JP (8) JP6497760B2 (da)
KR (4) KR102040235B1 (da)
CN (2) CN113801225A (da)
AU (2) AU2016253886B2 (da)
CA (1) CA2983898A1 (da)
CL (1) CL2017002729A1 (da)
CO (1) CO2017011975A2 (da)
CR (2) CR20170539A (da)
CY (1) CY1122569T1 (da)
DK (1) DK3290441T3 (da)
DO (1) DOP2017000248A (da)
ES (1) ES2758480T3 (da)
GT (1) GT201700224A (da)
HR (1) HRP20192099T1 (da)
HU (1) HUE047146T2 (da)
IL (2) IL287291B (da)
LT (1) LT3290441T (da)
MX (2) MX392169B (da)
NZ (2) NZ775372A (da)
PE (2) PE20180251A1 (da)
PH (1) PH12017501941A1 (da)
PL (1) PL3290441T3 (da)
PT (1) PT3290441T (da)
RS (1) RS59847B1 (da)
RU (1) RU2705304C2 (da)
SA (1) SA517390230B1 (da)
SG (1) SG11201708848TA (da)
SI (1) SI3290441T1 (da)
TW (4) TW202521584A (da)
WO (1) WO2016175236A1 (da)
ZA (2) ZA201708047B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2983898A1 (en) * 2015-04-28 2016-11-03 Mitsubishi Tanabe Pharma Corporation Rgma binding protein and use thereof
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
EP3631287B1 (en) * 2017-05-25 2021-07-07 Signify Holding B.V. Luminaire
AU2019301336B2 (en) 2018-07-10 2022-11-24 Mitsubishi Tanabe Pharma Corporation Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized
PE20260298A1 (es) * 2018-07-19 2026-02-10 Univ School St Marianna Medicine Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo de tratamiento del ham
AR120898A1 (es) * 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
MX2022008588A (es) * 2020-01-15 2022-08-10 Univ Osaka Agente profilactico o terapeutico para demencia.
WO2021145432A1 (ja) 2020-01-15 2021-07-22 国立大学法人大阪大学 糖尿病性自律神経障害の予防又は治療剤
CN112138146B (zh) * 2020-09-25 2022-08-09 安徽医科大学 Manf蛋白的应用
AR124914A1 (es) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4
CN120152741A (zh) 2022-11-07 2025-06-13 国立大学法人大阪大学 异常蛋白的聚集体蓄积所参与的疾病的预防或治疗剂
JPWO2025070749A1 (da) 2023-09-29 2025-04-03

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5565331A (en) 1993-11-12 1996-10-15 The Regents Of The University Of California Nucleic acids encoding neural axon outgrowth modulators
US5747262A (en) 1995-10-16 1998-05-05 The Regents Of The University Of California Neurological drug screens
US5824775A (en) 1996-04-19 1998-10-20 The Regents Of The University Of California Human netrin-1
US5939271A (en) 1997-02-19 1999-08-17 The Regents Of The University Of California Netrin receptor
AU735607B2 (en) 1997-08-13 2001-07-12 Yale University Central nervous system axon regeneration
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
WO2000032746A2 (en) 1998-11-30 2000-06-08 Millennium Pharmaceuticals, Inc. Netrin-like and ependymin-like nucleic acids and polypeptides and uses thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
US20030103945A1 (en) 2001-02-09 2003-06-05 Chen Dong Feng Methods and compositions for stimulating axon regeneration and preventing neuronal cell degeneration
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003089608A2 (en) 2002-04-18 2003-10-30 The General Hospital Corporation Drg11-responsive (dragon) gene family
CA2542171C (en) 2002-06-26 2015-12-15 Abbott Gmbh & Co. Kg Modulators and modulation of the interaction between rgm and neogenin
US20040199186A1 (en) 2003-04-04 2004-10-07 Kuffler Suzanne Elizabeth Implant to promote axon regeneration across spinal cord and peripheral nerve gaps
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CN1950108A (zh) * 2004-03-11 2007-04-18 生物线索株式会社 轴突再生促进剂
WO2005087268A1 (ja) 2004-03-11 2005-09-22 Bioclues, Inc 軸索再生促進剤
JP2008506703A (ja) 2004-07-14 2008-03-06 ユニバーシティ オブ ユタ リサーチ ファウンデーション ネトリン関連化合物および用途
US20060063208A1 (en) * 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
US7449442B2 (en) 2005-07-12 2008-11-11 Children's Medical Center Corporation EGFR inhibitors promote axon regeneration
CN101277974A (zh) * 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
US20080051319A1 (en) 2006-08-22 2008-02-28 Children's Medical Center Corporation Inhibiting JNK Signaling Promotes CNS Axon Regeneration
WO2008038599A1 (en) * 2006-09-25 2008-04-03 National University Corporation Chiba University Axonal regeneration promoter
EP1906185A1 (en) 2006-09-26 2008-04-02 ProteoSys AG Use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1)
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
DE102008014880A1 (de) 2008-03-12 2009-09-17 Eberhard-Karls-Universität Tübingen Antientzündliches Polypeptid
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
CN101306193A (zh) 2008-05-15 2008-11-19 复旦大学 人神经突起生长素在制备创伤愈合药物中的应用
DK2502623T3 (da) 2008-06-06 2016-07-04 Children's Medical Center Corp Fremme af axonregeneration i det voksne cns ved styring af proteintranslation
JP2010146801A (ja) 2008-12-17 2010-07-01 Kurita Water Ind Ltd 微生物発電方法及び微生物発電装置
PH12012501070A1 (en) * 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
KR102284780B1 (ko) * 2009-12-09 2021-08-02 미쓰비시 타나베 파마 코퍼레이션 Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법
MX357708B (es) * 2011-12-14 2018-07-20 Abbvie Deutschland Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
WO2013113107A1 (en) 2012-02-03 2013-08-08 University Health Network Methods for promoting neuron survival, axonal growth and/or regeneration
GB201203180D0 (en) * 2012-02-24 2012-04-11 Okapi Sciences Nv Compounds for treating parvovirus infection
US20140242043A1 (en) 2013-02-23 2014-08-28 Stemnion, Inc. Methods for preventing or treating optic neuritis
RS57840B1 (sr) * 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
US20160271230A1 (en) 2013-09-17 2016-09-22 University Health Network (Uhn): Technology Development And Commercialization Agents directed against a cis rgma/neogenin interaction or lipid rafts and use of the same in methods of treatment
WO2015120138A2 (en) 2014-02-05 2015-08-13 Dana-Farber Cancer Institute, Inc. AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
CA2983898A1 (en) * 2015-04-28 2016-11-03 Mitsubishi Tanabe Pharma Corporation Rgma binding protein and use thereof
CN105925578A (zh) 2016-05-30 2016-09-07 东北师范大学 靶向沉默Neogenin的shRNA
IL301242A (en) * 2020-09-11 2023-05-01 Janssen Biotech Inc Multi-specific immune targeting molecules and uses thereof

Also Published As

Publication number Publication date
ES2758480T3 (es) 2020-05-05
AU2016253886A1 (en) 2017-12-14
RU2705304C2 (ru) 2019-11-06
JP2026032030A (ja) 2026-02-25
RU2017135353A3 (da) 2019-04-08
IL287291A (en) 2021-12-01
CR20200517A (es) 2021-01-12
JP2021106587A (ja) 2021-07-29
GT201700224A (es) 2019-07-26
JP7606196B2 (ja) 2024-12-25
KR20190124350A (ko) 2019-11-04
PL3290441T3 (pl) 2020-05-18
RU2019134410A (ru) 2020-03-03
KR20230173734A (ko) 2023-12-27
LT3290441T (lt) 2020-02-10
KR102451786B1 (ko) 2022-10-05
KR102613528B1 (ko) 2023-12-12
CA2983898A1 (en) 2016-11-03
JP2025029166A (ja) 2025-03-05
US20210277098A1 (en) 2021-09-09
JP7780158B2 (ja) 2025-12-04
DOP2017000248A (es) 2018-01-31
JP7306660B2 (ja) 2023-07-11
HRP20192099T1 (hr) 2020-03-06
SA517390230B1 (ar) 2021-06-09
US20180100012A1 (en) 2018-04-12
SI3290441T1 (sl) 2020-03-31
JPWO2016175236A1 (ja) 2018-04-19
JP7307446B2 (ja) 2023-07-12
BR112017022994A2 (pt) 2019-11-19
EP3584260A1 (en) 2019-12-25
TW202521584A (zh) 2025-06-01
TW202328205A (zh) 2023-07-16
MX392169B (es) 2025-03-21
IL255293A0 (en) 2017-12-31
JP2023030057A (ja) 2023-03-07
US11008388B2 (en) 2021-05-18
JP2023120374A (ja) 2023-08-29
PE20230381A1 (es) 2023-03-06
TWI732757B (zh) 2021-07-11
AU2016253886B2 (en) 2019-05-16
EP3290441B1 (en) 2019-10-30
RU2017135353A (ru) 2019-04-08
HUE047146T2 (hu) 2020-04-28
JP2019141048A (ja) 2019-08-29
JP6497760B2 (ja) 2019-04-10
EP3290441A1 (en) 2018-03-07
KR20220140023A (ko) 2022-10-17
AU2019210655A1 (en) 2019-08-22
WO2016175236A1 (ja) 2016-11-03
CO2017011975A2 (es) 2018-02-20
TW201710296A (zh) 2017-03-16
KR102040235B1 (ko) 2019-11-05
CN107531791A (zh) 2018-01-02
JP2023025285A (ja) 2023-02-21
CL2017002729A1 (es) 2018-06-08
SG11201708848TA (en) 2017-11-29
ZA201907773B (en) 2021-05-26
CY1122569T1 (el) 2021-01-27
TWI873350B (zh) 2025-02-21
MX2022005565A (es) 2022-06-09
IL287291B (en) 2022-09-01
KR20170138565A (ko) 2017-12-15
RS59847B1 (sr) 2020-02-28
JP6955721B2 (ja) 2021-10-27
US10287346B2 (en) 2019-05-14
IL255293B (en) 2021-10-31
CN113801225A (zh) 2021-12-17
CN107531791B (zh) 2021-09-07
TW202138389A (zh) 2021-10-16
EP3290441A4 (en) 2018-10-17
NZ775384A (en) 2024-12-20
PT3290441T (pt) 2019-12-02
CR20170539A (es) 2018-04-20
NZ775372A (en) 2024-12-20
HK1245808A1 (en) 2018-08-31
TWI873576B (zh) 2025-02-21
ZA201708047B (en) 2020-01-29
MX2017013894A (es) 2018-03-01
PH12017501941A1 (en) 2018-03-19
KR102854388B1 (ko) 2025-09-02
NZ737770A (en) 2024-09-27
PE20180251A1 (es) 2018-02-02
US20190270799A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
IL272524A (en) Clec9a binding agents and use thereof
IL262437A (en) Bispecific binding proteins and uses thereof
DK3390444T3 (da) Anti-tl1a-antigenbindende proteiner og anvendelser deraf
IL287291A (en) A protein that binds to rgma and its use
IL246921B (en) Binding proteins and methods of use thereof
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
DK3235830T3 (da) Interleukin-15-proteinkompleks og anvendelse deraf
DK3316909T5 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
DK3412302T3 (da) Modificerede fgf-21-polypeptider og anvendelser deraf
DK3265575T3 (da) Cd20-bindende molekyler og anvendelser deraf
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
PL3370768T3 (pl) Przeciwciała specyficznie wiążące pd-1 i ich zastosowania
DK3498292T3 (da) Uspa2-proteinkonstruktioner og anvendelser deraf
DK3319612T3 (da) Oxysteroler og fremgansmåder til anvendelse derfor
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
IL250796A0 (en) Binding proteins specific for lox1 and uses thereof
DK3265641T3 (da) Stigørenhed og fremgangsmåde